An evaluation of glasdegib for the treatment of acute myelogenous leukemia.

An evaluation of glasdegib for the treatment of acute myelogenous leukemia.
Expert Opin Pharmacother. 2020 Feb 06;:1-8
Authors: Thomas X, Heiblig M
Abstract
Introduction: Despite recent advances in the treatment of adult acute myelogenous leukemia (AML), the overall outcome remains dismal especially in high-risk AML patients, including the elderly and the relapsed/refractory populations. In this setting, various clinical trials have recently explored novel therapeutic agents either used alone or in combination with intensive chemotherapy or low-intensity treatments.Areas covered: The current paper reviews the clinical development of glasdegib, a selective inhibitor of the Hedgehog signaling pathway through binding to its target SMO, for the treatment of AML.Expert opinion: Glasdegib confirmed its efficacy and showed an acceptable tolerability, especially when used in combination either with '3 + 7' chemotherapy or with low-intensity therapies. In 2018, glasdegib was approved by the Food and Drug Administration (FDA) in combination with low-dose cytarabine for the treatment of newly diagnosed AML in patients older than 75 years or presenting with severe comorbidities.
PMID: 32027196 [PubMed - as supplied by publisher]

Source: Expert Opinion on Pharmacotherapy - February 8, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research